nsc-87877 has been researched along with Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bu, H; Yang, CY; Yuan, X; Zhang, H; Zhou, J | 1 |
| Song, Y; Wang, S; Yang, X; Yu, B; Zhao, M | 1 |
| Bae, EA; Kang, CY; Kim, EK; Kim, TG; Lee, KA; Lee, YS; Song, YC | 1 |
2 review(s) available for nsc-87877 and Neoplasms
| Article | Year |
|---|---|
Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Crystallography, X-Ray; Drug Development; Enzyme Inhibitors; Human-Animal Bond; Humans; Models, Molecular; Molecular Structure; Mutation; Neoplasms; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Signal Transduction | 2020 |
Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Drug Design; Drug Discovery; Enzyme Inhibitors; Humans; Neoplasms; Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 2022 |
1 other study(ies) available for nsc-87877 and Neoplasms
| Article | Year |
|---|---|
A multimeric carcinoembryonic antigen signal inhibits the activation of human T cells by a SHP-independent mechanism: a potential mechanism for tumor-mediated suppression of T-cell immunity.
Topics: Carcinoembryonic Antigen; Cell Adhesion; Cell Line; Cell Proliferation; Gene Expression Regulation; HeLa Cells; Humans; Immune Tolerance; Lymphocyte Activation; Neoplasms; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Quinolines; Receptors, Antigen, T-Cell; Signal Transduction; T-Lymphocytes | 2015 |